


IN THE CLAIMS:

Please cancel claim 44 without prejudice or disclaimer.

In accordance with 37 C.F.R. § 1.121(c)(1), please substitute for claims 24 and 41, the following rewritten version of the same claim, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

24. (Amended) A method of treating a tumor, comprising administering to a human patient a radiolabeled peptide and a pharmaceutically acceptable carrier, wherein said radiolabeled peptide is prepared by contacting a solution of a peptide with stannous ions, wherein said peptide comprises a radiometal-binding moiety comprising the structure:



wherein R¹, R², and R³ independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of R¹, R², or R³ is H,

R⁵, R⁷, R⁸, R⁹ and R¹⁰ independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, and R⁸ and R⁹ together or R⁷ and R⁹ together may form a cycloalkyl or substituted cycloalkyl ring,

R⁴ and R⁶ together form a direct bond or are independently selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, and substituted aryl, and wherein NR¹⁰ is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide,

and then contacting said solution with a radionuclide and recovering the

C2
com.

radiolabeled peptide.

41. (Amended) A method according to claim 24, wherein said peptide is selected from the group consisting of:

(Chel) γ AbuNleDHF_d RWK-NH₂, (SEQ ID NO:1)

(Chel) γ AbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:2)

KPRRPYTDNYTRLRK(Chel)QMAVKKYLNSILN-NH₂, (SEQ ID NO:3)

(Chel) γ AbuVFTDNYTRLRKQMAVKKYLNSILN-NH₂,

(Chel) γ AbuYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:4)

HSDAVFTDNYTRLRK(Chel)QMAVKKYLNSILN-NH₂, (SEQ ID NO:5)

(SEQ ID NO:6) <GHWSYK(Chel)LRPG-NH₂, <GHYSLK(Chel)WKPG-NH₂, (SEQ ID NO:7)

AcNal_d Cpa_d W_d SRK_d (Chel)LRPA_d -NH₂, (SEQ ID NO:8)

(SEQ ID NO:9) (Chel) γ AbuSYSNleDHF_d RWK-NH₂, Ac-

HSDAVFTENYTKLRK(Chel)QNleAAKKYLNDLKKGGT-NH₂, (SEQ ID NO:10)

(SEQ ID NO:12) Nal_d Cpa_d W_d SRK_d (Chel)WKPG-NH₂, <GHWSYK_d (Chel)LRPG-NH₂, (SEQ ID NO:13)

(SEQ ID NO:14) AcK(Chel)F_d CFW_d KTCT-OH, AcK(Chel)DF_d CFW_d KTCT-OH, (SEQ ID NO:15)

(SEQ ID NO:14) AcK(Chel)F_d CFW_d KTCT-ol, AcK(Chel)DF_d CFW_d KTCT-ol, (SEQ ID NO:15)

(SEQ ID NO:16) (Chel)DF_d CFW_d KTCT-OH, K(Chel)DF_d CFW_d KTCT-ol, (SEQ ID NO:15)

(SEQ ID NO:17) K(Chel)KKF_d CFW_d KTCT-ol, K(Chel)KDF_d CFW_d KTCT-OH, (SEQ ID NO:18)

(SEQ ID NO:19) K(Chel)DSF_d CFW_d KTCT-OH, K(Chel)DF_d CFW_d KTCT-OH, (SEQ ID NO:15)

(SEQ ID NO:20) K(Chel)DF_d CFW_d KTCD-NH₂, K(Chel)DF_d CFW_d KTCT-NH₂, (SEQ ID NO:15)

(SEQ ID NO:18) K(Chel)KDF_d CFW_d KTCT-NH₂, AcK(Chel)F_d CFW_d KTCT-NH₂, (SEQ ID NO:14)

(SEQ ID NO:14) K(Chel)F_d CFW_d KTCT-ol, and F_d CFW_d KTCTK(Chel)-NH₂, (SEQ ID